Global Reach Cisiv’s Baseline Plus platform supports site-based, decentralized, and hybrid research and is used by 90% of the top global pharmaceutical companies, signaling strong potential to upsell broader data collection modules and expanded study types to existing high-profile clients.

Cost Efficiency Platform claims to reduce data management costs by 60%, presenting a compelling value proposition for prospective buyers facing data handling burdens and budget constraints in late-phase trials and real-world evidence programs.

Integrated Capabilities Baseline Plus covers end-to-end real-world data capture including EDC, eConsent, ePRO, eCOA, eDiary, Surveys, Safety, and e-Source, creating cross-sell opportunities to existing pharma and biotech customers seeking a single, modular solution.

Strategic Partnerships Past collaborations with Claret Capital and Clinerion indicate an openness to investment and data integration partnerships, suggesting avenues for co-marketing, blended service offerings, or channel partnerships to accelerate adoption.

Growth Indicators Revenue is in the low single-digit millions with modest funding, coupled with a small to mid-sized employee base, implying a focused sales approach toward mid-market pharma and biotech firms seeking scalable RWE capabilities and proven deployment success.